A combined discipline of medical oncology, which may be defined as the non-surgical, non-radiotherapeutic management of patients with solid tumours and clinical pharmacology, based on classic cytotoxic chemotherapy and the new signal transduction inhibitors. Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop 'personalized' medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers.
- Track 1-1 Percision Medicine
- Track 2-2 Tumour Associated Macrophages
- Track 3-3 Nanoparticle Based Delivery Systems
- Track 4-4 Molecular Targeting